Bavarian Nordic's MVA-BN patent stands in European validity challenge
The patent was granted in December 2005 and after the nine month opposition period in which any third party can file an opposition against any patent granted in a European jurisdiction, seven companies opposed the patent. The opposition proceeding has been pending at the European Patent Office for several years.
After an oral hearing in the first instance the Opposition Division today rendered its decision to uphold the patent with certain amended claims.
Bavarian Nordic's President & CEO, Anders Hedegaard commented: "We are very pleased with the decision by the first instance to uphold our core patent, thus confirming its uniqueness. We have substantially invested our resources to develop our MVA BN® technology and our efforts have led to the creation of valuable intellectual property, which we successfully have defended today."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.